Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Modality
Small molecule
Development Phase
Phase 2/3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
46Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01434108CT.gov Effects of the Administration of Ornithine Phenylacetate in Patients With Cirrhosis and Upper Gastrointestinal Bleeding | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Esophageal Varices With Bleeding
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ornithine (this asset) | Hospital Universitari Vall d'Hebron Research Institute | P2/3 | B · 61 |
| Apsolol | West China Hospital | P4 | BBB |
| Normal Human Serum Albumin | King George's Medical University | P4 | BB |
| Carvedilol | West China Hospital | P4 | BB |
| Phytonadione, (E)-(±)- | Tanta University | P4 | BB |
| Nadolol | National Science and Technology Council, Taiwan | P4 | BB |
| Midodrine | Hospital Clinic of Barcelona | P4 | BB |
| Tranexamic Acid | Tanta University | P4 | BB |
| Simvastatin | Juan A. Arnaiz | P3 | BB |
+7 more in the Esophageal Varices With Bleeding cohort
Other indications for Ornithine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cirrhosis Of Liver | — | P2/3 | BB · 67 |
| Hepatic Encephalopathy | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ornithine in Esophageal Varices With Bleeding. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ornithine-esophageal-varices-with-bleeding
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →